These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16913647)

  • 1. The new meningococcal conjugate vaccine. A profile of its safety, efficacy, and indications for use.
    Pichichero ME
    Postgrad Med; 2006; 119(1):47-54, 64. PubMed ID: 16913647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal conjugate vaccine in adolescents and children.
    Pichichero ME
    Clin Pediatr (Phila); 2005; 44(6):479-89. PubMed ID: 16015394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
    Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
    Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunities for control of meningococcal disease in the United States.
    Raghunathan PL; Bernhardt SA; Rosenstein NE
    Annu Rev Med; 2004; 55():333-53. PubMed ID: 14746525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal vaccine evolution.
    Bona G; Guidi C
    J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.
    Macneil JR; Cohn AC; Zell ER; Schmink S; Miller E; Clark T; Messonnier NE;
    Pediatr Infect Dis J; 2011 Jun; 30(6):451-5. PubMed ID: 21206392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection.
    Pace D
    Curr Opin Mol Ther; 2009 Dec; 11(6):692-706. PubMed ID: 20072946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
    Pace D
    Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal conjugate vaccines.
    Pichichero ME
    Expert Opin Biol Ther; 2005 Nov; 5(11):1475-89. PubMed ID: 16255651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
    Pace D; Pollard AJ
    Arch Dis Child; 2007 Oct; 92(10):909-15. PubMed ID: 17895339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2009 Apr; 35(ACS-3):1-40. PubMed ID: 19400026
    [No Abstract]   [Full Text] [Related]  

  • 15. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
    Trotter CL; Ramsay ME
    FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of invasive meningococcal disease: is it achievable?
    Marshall H; Wang B; Wesselingh S; Snape M; Pollard AJ
    Int J Evid Based Healthc; 2016 Mar; 14(1):3-14. PubMed ID: 26126001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.
    Cooper B; DeTora L; Stoddard J
    Expert Rev Vaccines; 2011 Jan; 10(1):21-33. PubMed ID: 21162617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of MenACWY-CRM in adolescents in the United States.
    Black S; Block SL
    J Adolesc Health; 2013 Mar; 52(3):271-7. PubMed ID: 23299001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2010 FIFA world cup South Africa: travel health issues and new options for protection against meningococcal disease.
    Zuckerman JN; Bröker M; Worth C
    Travel Med Infect Dis; 2010 Mar; 8(2):68-73. PubMed ID: 20478511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.